Coloplast A/s Class B · OMXCOP:COLO_B

Coloplast A/s Class B — H1 2021/22 Earnings Presentation

10 slides from Coloplast A/s Class B's earnings presentation, 2022

  1. Slide 1: Coloplast earnings conference call H1 2021/22

    Coloplast earnings conference call H1 2021/22 Making life SpeediCath® Flex Set easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care

  2. Slide 2: Forward-looking statements

    Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements

  3. Slide 3: Solid Q2 organic growth of 7% and 31% EBIT margin

    Solid Q2 organic growth of 7% and 31% EBIT margin1. Atos Medical contributed 6%-p to reported growth, in line with expectations REVENUE GROWTH Q2 2021/22 highlights Reported revenue (mDKK) Organic growth Reported growth • Organic growth of 7% and reported growth in DKK of 16%. Atos Medical contribut

  4. Slide 4: Solid progress on the Strive25 strategy – Sustainable Growth Leadership

    Solid progress on the Strive25 strategy – Sustainable Growth Leadership Growth Innovation . Atos Medical acquisition Chronic Care – Clinical Performance Programme - Adding a new chronic care business segment, Voice & Respiratory Care - New ostomy platform – the pivotal study to test the new skin pro

  5. Slide 5: Q2 growth was driven by the Chronic Care business in Europe and Emerging Markets

    Q2 growth was driven by the Chronic Care business in Europe and Emerging Markets excluding China Q2 2021/22 revenue by business area Q2 2021/22 revenue by geography Business Reported revenue Q2 Organic growth Share of organic Geographic Reported revenue Q2 Organic growth Share of organic area DKKm Q

  6. Slide 6: H1 reported growth was up 12%, with ~3%-points positive impact from the Atos acquisition

    H1 reported growth was up 12%, with ~3%-points positive impact from the Atos acquisition and ~3%-points impact from currencies H1 Revenue development (DKKm) Highlights • Reported revenue increased by DKK 1,180 million, or 12% vs. last year • H1 organic growth was 6% or DKK 613 million, driven by: 25

  7. Slide 7: Reported EBIT margin of 31% in H1 reflecting increased level of commercial activity

    Reported EBIT margin1 of 31% in H1 reflecting increased level of commercial activity, partly offset by efficiency gains and FX H1 EBIT margin development before special items (%) Highlights • H1 gross margin was 69%, against 68% in H1 last year • Positive impact from operating leverage and savings f

  8. Slide 8: FCF driven by solid underlying development in earnings and impacted by Atos Medical

    FCF driven by solid underlying development in earnings and impacted by the Atos Medical acquisition FCF development Comments Highlights • Free cash flow was an outflow of DKK 9,715 million compared to an inflow of DKK 446 million in H1 2020/21 98 99 98 93 • Adjusted for acquisitions, the free cash f

  9. Slide 9: Organic growth guidance for FY 2021/22 updated to 6-7%, due to COVID-19 impact in China

    Organic growth guidance for FY 2021/22 updated to 6-7%, due to COVID-19 impact in China GUIDANCE 2021/22 GUIDANCE (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalised growth in ne

  10. Slide 10: Page 10

    Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care Page 10

Coloplast — H1 2021/22 Earnings Presentation on 6ix